Jason Fangusaro1, Arzu Onar-Thomas2, Tina Young Poussaint3,4, Shengjie Wu2, Azra H Ligon5, Neal Lindeman5, Olivia Campagne6, Anu Banerjee7, Sridharan Gururangan8, Lindsay B Kilburn9, Stewart Goldman10,11, Ibrahim Qaddoumi12, Patricia Baxter13,14, Gilbert Vezina15, Corey Bregman16, Zoltan Patay17, Jeremy Y Jones18, Clinton F Stewart6, Michael J Fisher19,20, Laurence Austin Doyle21, Malcolm Smith22, Ira J Dunkel23,24, Maryam Fouladi25. 1. Department of Hematology, Oncology, and Stem Cell Transplantation, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA. 2. Department of Biostatistics St. Jude Children's Research Center, Memphis, Tennessee, USA. 3. St. Jude Children's Research Center, Memphis, Tennessee, USA. 4. Department of Radiology, Boston Children's Hospital, Boston, Massachusetts, USA. 5. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6. Department of Pharmaceutical Sciences St. Jude Children's Research Center, Memphis, Tennessee, USA. 7. Center for Cancer and Blood Disorders, University of California, San Francisco, California, USA. 8. Department of Neurosurgery, University of Florida, Gainesville, Florida, USA. 9. Division of Oncology Children's National Hospital , Washington DC, USA. 10. Children's National Hospital, Washington DC, USA. 11. Department of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation. 12. Department of Oncology St. Jude Children's Research Center, Memphis, Tennessee, USA. 13. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. 14. Department of Hematology and Oncology, Texas Children's Hospital, Houston, Texas, USA. 15. Department of Radiology Children's National Hospital , Washington DC, USA. 16. Department of Medical Imaging. 17. Department of Diagnostic Imaging St. Jude Children's Research Center, Memphis, Tennessee, USA. 18. Department of Radiology Nationwide Children's Hospital, Columbus, Ohio, USA. 19. Nationwide Children's Hospital, Columbus, Ohio, USA. 20. Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 21. Investigational Drug Branch, National Cancer Institute and Cancer Therapy Evaluation Program, Rockville, Maryland, USA. 22. Clinical Investigation Branch, National Cancer Institute and Cancer Therapy Evaluation Program, Rockville, Maryland, USA. 23. National Cancer Institute and Cancer Therapy Evaluation Program, Rockville, Maryland, USA. 24. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 25. Department of Hematology and Oncology Nationwide Children's Hospital, Columbus, Ohio, USA.
Abstract
BACKGROUND: Pediatric low-grade gliomas (pLGGs) are the most common childhood brain tumor. Progression-free survival (PFS) is much lower than overall survival, emphasizing the need for alternative treatments. Sporadic (without neurofibromatosis type 1) optic pathway and hypothalamic gliomas (OPHGs) are often multiply recurrent and cause significant visual deficits. Recently, there has been a prioritization of functional outcomes. METHODS: We present results from children with recurrent/progressive OPHGs treated on a PBTC (Pediatric Brain Tumor Consortium) phase II trial evaluating efficacy of selumetinib (AZD6244, ARRY-142886) a MEK-1/2 inhibitor. Stratum 4 of PBTC-029 included patients with sporadic recurrent/progressive OPHGs treated with selumetinib at the recommended phase II dose (25mg/m2/dose BID) for a maximum of 26 courses. RESULTS: Twenty-five eligible and evaluable patients were enrolled with a median of 4 (1-11) previous therapies. Six of 25 (24%) had partial response, 14/25 (56%) had stable disease, and 5 (20%) had progressive disease while on treatment. The median treatment courses were 26 (2-26); 14/25 patients completed all 26 courses. Two-year PFS was 78 ± 8.5%. Nineteen of 25 patients were evaluable for visual acuity which improved in 4/19 patients (21%), was stable in 13/19 (68%), and worsened in 2/19 (11%). Five of 19 patients (26%) had improved visual fields and 14/19 (74%) were stable. The most common toxicities were grade 1/2 CPK elevation, anemia, diarrhea, headache, nausea/emesis, fatigue, AST and ALT increase, hypoalbuminemia, and rash. CONCLUSIONS: Selumetinib was tolerable and led to responses and prolonged disease stability in children with recurrent/progressive OPHGs based upon radiographic response, PFS, and visual outcomes.
BACKGROUND: Pediatric low-grade gliomas (pLGGs) are the most common childhood brain tumor. Progression-free survival (PFS) is much lower than overall survival, emphasizing the need for alternative treatments. Sporadic (without neurofibromatosis type 1) optic pathway and hypothalamic gliomas (OPHGs) are often multiply recurrent and cause significant visual deficits. Recently, there has been a prioritization of functional outcomes. METHODS: We present results from children with recurrent/progressive OPHGs treated on a PBTC (Pediatric Brain Tumor Consortium) phase II trial evaluating efficacy of selumetinib (AZD6244, ARRY-142886) a MEK-1/2 inhibitor. Stratum 4 of PBTC-029 included patients with sporadic recurrent/progressive OPHGs treated with selumetinib at the recommended phase II dose (25mg/m2/dose BID) for a maximum of 26 courses. RESULTS: Twenty-five eligible and evaluable patients were enrolled with a median of 4 (1-11) previous therapies. Six of 25 (24%) had partial response, 14/25 (56%) had stable disease, and 5 (20%) had progressive disease while on treatment. The median treatment courses were 26 (2-26); 14/25 patients completed all 26 courses. Two-year PFS was 78 ± 8.5%. Nineteen of 25 patients were evaluable for visual acuity which improved in 4/19 patients (21%), was stable in 13/19 (68%), and worsened in 2/19 (11%). Five of 19 patients (26%) had improved visual fields and 14/19 (74%) were stable. The most common toxicities were grade 1/2 CPK elevation, anemia, diarrhea, headache, nausea/emesis, fatigue, AST and ALT increase, hypoalbuminemia, and rash. CONCLUSIONS: Selumetinib was tolerable and led to responses and prolonged disease stability in children with recurrent/progressive OPHGs based upon radiographic response, PFS, and visual outcomes.
Authors: Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Scott Ryall; Michal Zapotocky; Kohei Fukuoka; Liana Nobre; Ana Guerreiro Stucklin; Julie Bennett; Robert Siddaway; Christopher Li; Sanja Pajovic; Anthony Arnoldo; Paul E Kowalski; Monique Johnson; Javal Sheth; Alvaro Lassaletta; Ruth G Tatevossian; Wilda Orisme; Ibrahim Qaddoumi; Lea F Surrey; Marilyn M Li; Angela J Waanders; Stephen Gilheeney; Marc Rosenblum; Tejus Bale; Derek S Tsang; Normand Laperriere; Abhaya Kulkarni; George M Ibrahim; James Drake; Peter Dirks; Michael D Taylor; James T Rutka; Suzanne Laughlin; Manohar Shroff; Mary Shago; Lili-Naz Hazrati; Colleen D'Arcy; Vijay Ramaswamy; Ute Bartels; Annie Huang; Eric Bouffet; Matthias A Karajannis; Mariarita Santi; David W Ellison; Uri Tabori; Cynthia Hawkins Journal: Cancer Cell Date: 2020-04-13 Impact factor: 31.743
Authors: A J Janss; R Grundy; A Cnaan; P J Savino; R J Packer; E H Zackai; J W Goldwein; L N Sutton; J Radcliffe; P T Molloy Journal: Cancer Date: 1995-02-15 Impact factor: 6.860
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Michael J Wan; Nicole J Ullrich; Peter E Manley; Mark W Kieran; Liliana C Goumnerova; Gena Heidary Journal: J Neurooncol Date: 2016-06-16 Impact factor: 4.130
Authors: Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu Journal: Neurology Date: 2013-11-19 Impact factor: 9.910
Authors: S Vajapeyam; D Brown; A Ziaei; S Wu; G Vezina; J S Stern; A Panigrahy; Z Patay; B Tamrazi; J Y Jones; S S Haque; D S Enterline; S Cha; B V Jones; K W Yeom; A Onar-Thomas; I J Dunkel; M Fouladi; J R Fangusaro; T Y Poussaint Journal: AJNR Am J Neuroradiol Date: 2022-02-24 Impact factor: 3.825
Authors: D Williams Parsons; Katherine A Janeway; David R Patton; Cynthia L Winter; Brent Coffey; P Mickey Williams; Sinchita Roy-Chowdhuri; Gregory J Tsongalis; Mark Routbort; Nilsa C Ramirez; Lauren Saguilig; Jin Piao; Todd A Alonzo; Stacey L Berg; Elizabeth Fox; Douglas S Hawkins; Jeffrey S Abrams; Margaret Mooney; Naoko Takebe; James V Tricoli; Nita L Seibel Journal: J Clin Oncol Date: 2022-03-30 Impact factor: 50.717
Authors: Olive S Eckstein; Carl E Allen; P Mickey Williams; Sinchita Roy-Chowdhuri; David R Patton; Brent Coffey; Joel M Reid; Jin Piao; Lauren Saguilig; Todd A Alonzo; Stacey L Berg; Nilsa C Ramirez; Alok Jaju; Joyce Mhlanga; Elizabeth Fox; Douglas S Hawkins; Margaret M Mooney; Naoko Takebe; James V Tricoli; Katherine A Janeway; Nita L Seibel; D Williams Parsons Journal: J Clin Oncol Date: 2022-04-01 Impact factor: 50.717
Authors: Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 13.029